Life science entrepreneur, Dr. Scott Rocklage, strives to revolutionize how medical professionals apply results-oriented research to clinical practices. In an effort to breathe life into this philosophy, he landed his role at the life sciences capitalist, 5AM Ventures, LLC. He initially agreed to a partnership in 2003 before making a managing partner a year later.
The firm capitalized on his extensive hands-on experience and results-oriented strategies, which bolstered a network-driven agenda, focused on enabling the wider medical community. Among those remunerating his consulting services are research scientists, industry executives, and physicians. Dr. Rocklage recommends strategies that primarily focuses on leadership selection, enterprising professionals, and technologies that accelerate productivity.
He’s quite the futurist who strongly advocates for scientific research that’s pushing the barriers of medicine and healthcare advancements. His intervention has led to the FDA approving: Omniscan, Teslascan, and Cubicin.
All three advanced drugs are richly associated with modern cancer treatment today. With recent developments in cancer treatment, where scientists discovered how to effectively target genotypes, mutation and more, it’s easier to reach an accurate prognosis.
What’s more, suggesting the right course of treatment for recovery following early detection and preventing relapse is far less challenging. With a sparse of opportunities extended to practitioners in pursuit of unorthodox life science dreams, Dr. Rocklage’s presence at 5AM Ventures has motivated rewarding success. Learn more about Scott Rocklage: http://people.equilar.com/bio/scott-rocklage-cidara-therapeutics-/salary/913398#.WWaMA9PytTY
A well-cultured healthcare industry pioneer and life science intellectual, Dr. Rocklage has played an instrumental role in developing 30+ US-approved drug patents. Similarly, he’s authored some 100+ publications addressed to peer research gatekeepers.
An MIT (Massachusetts Institute of Technology) alumnus, Dr. Rocklage credits the institution, particularly the chemistry hub for his comprehensive education. It’s enabled his ambitions to explore emerging frontiers of medicine and life sciences.
Scott holds a doctoral degree in Chemistry from the same university. He recounts a memorable collaborative research effort at MIT, working as an apprentice to Nobel laureate and decorated American chemist, Richard Royce Schrock.
Prior to joining 5AM Ventures, he assumed leadership of numerous pharmaceutical and biochemical giants. At Nycomed Salutar, he assumed the designation of principal executive and became the company’s president. He’s the former chair of Novira Therapeutics, which is now a J&J subsidiary.